List of Orserdu drug patents

Orserdu is owned by Stemline Therap.

Orserdu contains Elacestrant Dihydrochloride.

Orserdu has a total of 3 drug patents out of which 0 drug patents have expired.

Orserdu was authorised for market use on 27 January, 2023.

Orserdu is available in tablet;oral dosage forms.

Orserdu can be used as treatment of an er-positive breast cancer following at least one line of endocrine therapy, treatment of an er-positive breast cancer.

Drug patent challenges can be filed against Orserdu from 2027-01-27.

The generics of Orserdu are possible to be released after 05 January, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8399520 STEMLINE THERAP Selective estrogen receptor modulator
Dec, 2023

(8 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071066 STEMLINE THERAP Method of treating cancer using selective estrogen receptor modulators
Oct, 2034

(11 years from now)

US10745343 STEMLINE THERAP Polymorphic forms of RAD1901-2HCl
Jan, 2038

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 27, 2028

Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-01-27

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of an er-positive breast cancer following at least one line of endocrine therapy; Treatment of an er-positive breast cancer


More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in